Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms.

doi: 10.1158/1078-0432.CCR-22-1763

Figure Lengend Snippet: Figure 1: Crizotinib suppresses proliferation of JAK2V617F PV cells in vivo and in vitro (A) Trend in hematocrit of a patient with EML4-ALK lung cancer while on ALK inhibitors (B) Number of total colony forming units (CFU) and burst forming units-erythroid (BFU-E) colonies from CD34+ cells from this patient’s peripheral blood treated ex vivo with ALK inhibitors. ANOVA with Tukey’s multiple-comparison tests was used. (C) Representative BFU-E colonies (D) Phospho-flow cytometry analysis of STAT5 phosphorylation in this patient’s erythroblasts with crizotinib, ceritinib, or alectinib inhibitor treatment stimulated with EPO ex vivo. Cells are gated on the CD71hi CD34neg doublet negative cells population *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Data represent mean ± SEM.

Article Snippet: Pre-warmed 2.5mL human StemMACS complete media containing EPO (Miltenyi Biotec, Cat #130-091-280) aliquots were treated with the indicated inhibitor or 30% DMSO in 1X PBS as control.

Techniques: In Vivo, In Vitro, Ex Vivo, Comparison, Flow Cytometry, Phospho-proteomics

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms.

doi: 10.1158/1078-0432.CCR-22-1763

Figure Lengend Snippet: Figure 2: Crizotinib inhibits proliferation and JAK/STAT signaling in MPN cells in a dose- dependent manner (A) Colony formation assays of MPN peripheral blood CD34+ cells with ex vivo crizotinib treatment (0.5μM: N=7, 1μM: N=19). ANOVA with Tukey’s multiple-comparison test was used (B) Colony formation assay of MPN CD34+ cells with ex vivo crizotinib treatment, categorized by the patient’s current JAK inhibitor (JAKi) status (JAK2i treated: N=7, untreated: N=5) (A-B) Colony numbers were normalized to the DMSO control for each patient. (C) Flow cytometry analysis of STAT3 and STAT5 phosphorylation in PMF patient erythroblasts with crizotinib (criz) or ruxolitinib (rux) inhibitor treatment ex vivo stimulated with EPO, SCF, and hepatocyte growth factor (HGF) (D) Schematic for treatment of JAK2V617F-loxP/+;Vav1-Cre mice and JAK2V617F-loxP/+ controls with crizotinib or vehicle (E) Spleen weights of JAK2V617F-loxP/+;Vav1-Cre mice and controls after 3 week treatment with crizotinib (N=7) or vehicle (N=12) (F) Representative H&E images of bone marrow from JAK2V617F-loxP/+;Vav1-Cre mice treated with crizotinib or vehicle. Images were taken at 10X magnification. (G) Dose-response curves from cell viability assays in the JAK2-V617F mutant cell lines HEL and SET2 and the EML4-ALK rearranged non-small cell lung cancer cell line H3122 after 3 days of crizotinib treatment. Experiments were performed at least three times, with similar results (H) Western blot analysis of JAK/STAT signaling in HEL cells treated with crizotinib, ceritinib, or ruxolitinib and stimulated with

Article Snippet: Pre-warmed 2.5mL human StemMACS complete media containing EPO (Miltenyi Biotec, Cat #130-091-280) aliquots were treated with the indicated inhibitor or 30% DMSO in 1X PBS as control.

Techniques: Ex Vivo, Comparison, Colony Assay, Control, Flow Cytometry, Phospho-proteomics, Mutagenesis, Western Blot

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms.

doi: 10.1158/1078-0432.CCR-22-1763

Figure Lengend Snippet: Figure 3: Treatment of JAK inhibitor persistent cells with crizotinib is important for overcoming persistence (A) Cell Titer Glo proliferation assays of SET2-parental cells treated with crizotinib and/or ruxolitinib. For the final timepoint, ANOVA with Tukey’s multiple-comparison test was used (B) ZIP synergy scores for dose response matrix of SET2-persistent cells treated with crizotinib and/or ruxolitinib for 3 days (red represents synergy; green represents antagonism). (C) Western analysis of JAK/STAT signaling in SET2-persistent cells treated with ruxolitinib and/or crizotinib and stimulated with EPO and SCF (D) RON activation in SET2-parental or SET2-persistent cells (E-F) Co-immunoprecipitation and Western analysis of phospho-RON, phospho-JAK2, and JAK2 in SET2-ruxolitinib persistent cells in (E) untreated conditions or (F) with crizotinib and ruxolitinib combination treatment (Rux/Criz). Representative data from one of at least three independent experiments is shown. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Data represent mean ± SEM.

Article Snippet: Pre-warmed 2.5mL human StemMACS complete media containing EPO (Miltenyi Biotec, Cat #130-091-280) aliquots were treated with the indicated inhibitor or 30% DMSO in 1X PBS as control.

Techniques: Comparison, Western Blot, Activation Assay, Immunoprecipitation

Journal: Applied and Environmental Microbiology

Article Title: Diversity of Bacteria in the Marine Sponge Aplysina fulva in Brazilian Coastal Waters

doi: 10.1128/aem.02101-08

Figure Lengend Snippet: FIG. 3. Evolutionary relationships of 145 gammaproteobacterial 16S rRNA sequences. Twenty-seven sequences retrieved from a dominant “Pseudomonas” band observed to be enriched in A. fulva DGGE profiles (Fig. 2c) were included in phylogenetic inference. The evolutionary history was inferred by using the neighbor-joining method (49). The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to infer the phylogenetic tree. The evolutionary distances were computed by using the Kimura two-parameter method (29) and are in the units of the number of base substitutions per site (note the scale bar). Bootstrap values (1,000 repetitions) greater than 50% are shown on three nodes. There were a total of 413 aligned nucleotide positions in the final data set. The 16S rRNA gene sequences of Burkholderia cepacia (T) ATCC 25416T (Betaproteobacteria) and Streptomyces thermocoprophilus (T) (Actinobacteria) served as outgroups.

Article Snippet: The 16S rRNA gene sequences of Burkholderia cepacia (T) ATCC 25416T (Betaproteobacteria) and Streptomyces thermocoprophilus (T) (Actinobacteria) served as outgroups.

Techniques:

Journal:

Article Title: Transposition of the Heat-Stable Toxin astA Gene into a Gifsy-2-Related Prophage of Salmonella enterica Serovar Abortusovis

doi: 10.1128/JB.186.14.4568-4574.2004

Figure Lengend Snippet: Strains used in this study

Article Snippet: Finally, we made use of a collection of 67 serovar Abortusovis epidemic strains, of which 35 originated from Italy, 2 from France, 6 from Albania, 1 from Russia, 1 from the United Kingdom, and 22 from Iran. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Serovar and strain Relevant genotype Reference S. enterica serovar Abortusovis SS44 Wild type 1 15/5 Wild type 14 SSM2992 SS44 ΔGifsy-2AO::Km This study SSM2993 SS44 Δ gtgE ::Km This study SSM2994 SS44 Δ sodC1 ::Km This study SSM3227 SS44 Δ gtgE Δ sodC1 ::Km This study MA6776 SS44 araBA-5463 araD-2939 ::MudJ lac ::Tn 10 Tc This study MA6777 SS44 araBA-5463 araD-2939 ::MudJ lac This study SSM3239 SSM2992 araBA-5463 araD-2939 ::MudJ lac This study SSM3448 SSM2993 araBA-5463 araD-2939 ::MudJ lac This study SSM3449 SSM2994 araBA-5463 araD-2939 ::MudJ lac This study SSM3474 SSM3227 araBA-5463 araD-2939 ::MudJ lac ::Tn 10 Tc This study SSM916 SS44 invH201 ::Tn phoA 31 S. enterica serovar Typhimurium ATCC 14028s Wild type 6 SL1344 Wild type 13 Open in a separate window Strains used in this study Genetic procedures.

Techniques:

Journal: The Journal of antibiotics

Article Title: AcrA dependency of the AcrD efflux pump in Salmonella enterica serovar Typhimurium.

doi: 10.1038/ja.2011.28

Figure Lengend Snippet: Figure 1 Resistance-nodulation cell division (RND) transporter system genes encoded in the S. enterica serovar Typhimurium genome. Chromosomal positions of genes encoding RND drug transporters, outer membrane proteins and membrane fusion proteins (MFPs) are indicated by ‘kb’ (kilobase pair) in the S. enterica serovar Typhimurium strain LT2 genome.29 Figure was modified from Nishino et al. (2006).19 Arrows correspond to the lengths and directions of the genes.

Article Snippet: The transformant (DacrB/pacrD) showed increased resistance to SDS and novobiocin as we previously reported.19,20 Because we had previously cloned acrD into the pUC118 vector, which had the b-lactamase gene Table 1 S. enterica strains and plasmids used in this study Strain or plasmid Characteristics Source or reference Strains ATCC 14028s S. enterica serovar Typhimurium wild type 21 NKS1202 DacrB This study NKS1254 DacrB/pACYC177KmR This study NKS1255 DacrB/pacrA This study NKS1235 DacrB/pHSG398 This study NKS1236 DacrB/pacrD This study NKS234 DacrAB This study NKS1252 DacrAB/pACYC177KmR This study NKS1238 DacrAB/pHSG398 This study NKS1253 DacrAB/pACYC177KmR+pHSG398 This study NKS1240 DacrAB/pacrA This study NKS1241 DacrAB/pacrD This study NKS1242 DacrAB/pacrA+pacrD This study NKS1245 DacrABDacrD This study NKS1246 DacrABDacrD/pACYC177KmR This study NKS1247 DacrABDacrD/pHSG398 This study NKS1248 DacrABDacrD/pACYC177KmR+pHSG398 This study NKS1249 DacrABDacrD/pacrA This study NKS1250 DacrABDacrD/pacrD This study NKS1251 DacrABDacrD/pacrA+pacrD This study NKS233 DtolC This study NKS1243 DtolC/pHSG398 This study NKS1244 DtolC/pacrD This study

Techniques: Membrane

Journal: Artificial cells, nanomedicine, and biotechnology

Article Title: Weissella oryzae DC6-facilitated green synthesis of silver nanoparticles and their antimicrobial potential.

doi: 10.3109/21691401.2015.1064937

Figure Lengend Snippet: Figure 1. W. oryzae DC6 on TSA plate (a), W. oryzae DC6 on TSA plate supplemented with 1 mM AgNO3 (b). UV-Vis spectra of reaction mixture contain silver nanoparticles (c), respectively.

Article Snippet: Antimicrobial activity of silver nanoparticles against Staphylococcus aureus [ATCC 6538] (a), Candida albicans [KACC 30062] (b), Bacillus cereus [ATCC 14579] (c), Vibrio parahaemolyticus [ATCC 33844] (d), Escherichia coli [ATCC 10798] (e) and, Bacillus anthracis [NCTC 10340] (f ), respectively.

Techniques:

Journal: Artificial cells, nanomedicine, and biotechnology

Article Title: Weissella oryzae DC6-facilitated green synthesis of silver nanoparticles and their antimicrobial potential.

doi: 10.3109/21691401.2015.1064937

Figure Lengend Snippet: Figure 2. TEM image of spherical shaped silver nanoparticles at 20 nm (a) and 50 nm (b).

Article Snippet: Antimicrobial activity of silver nanoparticles against Staphylococcus aureus [ATCC 6538] (a), Candida albicans [KACC 30062] (b), Bacillus cereus [ATCC 14579] (c), Vibrio parahaemolyticus [ATCC 33844] (d), Escherichia coli [ATCC 10798] (e) and, Bacillus anthracis [NCTC 10340] (f ), respectively.

Techniques:

Journal: Artificial cells, nanomedicine, and biotechnology

Article Title: Weissella oryzae DC6-facilitated green synthesis of silver nanoparticles and their antimicrobial potential.

doi: 10.3109/21691401.2015.1064937

Figure Lengend Snippet: Figure 3. EDX spectrum of silver nanoparticles (a), XRD spectrum of silver nanoparticles (b), elemental mapping results indicate distribution of silver elements, TEM micrograph of silver nanoparticles pellet solution (c), and silver nanoparticles (d), respectively.

Article Snippet: Antimicrobial activity of silver nanoparticles against Staphylococcus aureus [ATCC 6538] (a), Candida albicans [KACC 30062] (b), Bacillus cereus [ATCC 14579] (c), Vibrio parahaemolyticus [ATCC 33844] (d), Escherichia coli [ATCC 10798] (e) and, Bacillus anthracis [NCTC 10340] (f ), respectively.

Techniques:

Journal: Artificial cells, nanomedicine, and biotechnology

Article Title: Weissella oryzae DC6-facilitated green synthesis of silver nanoparticles and their antimicrobial potential.

doi: 10.3109/21691401.2015.1064937

Figure Lengend Snippet: Figure 4. Particles size distribution of silver nanoparticles with respect to intensity, number and volume of silver nanoparticles.

Article Snippet: Antimicrobial activity of silver nanoparticles against Staphylococcus aureus [ATCC 6538] (a), Candida albicans [KACC 30062] (b), Bacillus cereus [ATCC 14579] (c), Vibrio parahaemolyticus [ATCC 33844] (d), Escherichia coli [ATCC 10798] (e) and, Bacillus anthracis [NCTC 10340] (f ), respectively.

Techniques:

Journal: Artificial cells, nanomedicine, and biotechnology

Article Title: Weissella oryzae DC6-facilitated green synthesis of silver nanoparticles and their antimicrobial potential.

doi: 10.3109/21691401.2015.1064937

Figure Lengend Snippet: Figure 6. Biofi lm inhibition activity of silver nanoparticles against Staphylococcus aureus [ATCC 6538] and Pseudomonas aeruginosa [ATCC 27853].

Article Snippet: Antimicrobial activity of silver nanoparticles against Staphylococcus aureus [ATCC 6538] (a), Candida albicans [KACC 30062] (b), Bacillus cereus [ATCC 14579] (c), Vibrio parahaemolyticus [ATCC 33844] (d), Escherichia coli [ATCC 10798] (e) and, Bacillus anthracis [NCTC 10340] (f ), respectively.

Techniques: Inhibition, Activity Assay

Journal: Artificial cells, nanomedicine, and biotechnology

Article Title: Weissella oryzae DC6-facilitated green synthesis of silver nanoparticles and their antimicrobial potential.

doi: 10.3109/21691401.2015.1064937

Figure Lengend Snippet: Figure 5. Antimicrobial activity of silver nanoparticles against Staphylococcus aureus [ATCC 6538] (a), Candida albicans [KACC 30062] (b), Bacillus cereus [ATCC 14579] (c), Vibrio parahaemolyticus [ATCC 33844] (d), Escherichia coli [ATCC 10798] (e) and, Bacillus anthracis [NCTC 10340] (f), respectively.

Article Snippet: Antimicrobial activity of silver nanoparticles against Staphylococcus aureus [ATCC 6538] (a), Candida albicans [KACC 30062] (b), Bacillus cereus [ATCC 14579] (c), Vibrio parahaemolyticus [ATCC 33844] (d), Escherichia coli [ATCC 10798] (e) and, Bacillus anthracis [NCTC 10340] (f ), respectively.

Techniques: Activity Assay